Autobahn expects topline data from the ongoing Phase II AMPLIFY-BD trial in adjunctive bipolar depression in the second quarter of 2026.
Elunetirom is designed to enhance neurobiological activity at CNS-TRs and reduce peripheral thyroid hormone-related risks. Credit: sasirin pamai / Shutterstock.com.
Autobahn Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for elunetirom, its lead central nervous system (CNS)-directed thyroid hormone receptor agonist.
Elunetirom is an oral, once daily, brain-penetrant CNS thyroid hormone receptor (CNS-TR) agonist in development for bipolar depression and major depressive disorder (MDD). Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
